Figure 2.
Overall survival stratified by FLC-MS positivity or negativity: (A) OS from diagnosis based on FLC-MS status at 12-month landmark analysis; median OS, NR vs 63 months (P ≤ .001) in those with FLC-MS negative vs positive. (B) OS from diagnosis based on FLC-MS status at 12-month landmark analysis in patients who achieved a hematologic CR; median OS was NR vs 108 months (P = .009) in those with FLC-MS negative vs positive. (C) Six month analysis of OS from diagnosis by hematologic response combined with FLC-MS Status. CR – FLC MS negative, median OS NR, CR – FLC MS positive 80 months, VGPR – FLC MS negative 85 months, VGPR – FLC MS positive 60 months. (D) Twelve month analysis of OS from diagnosis by hematologic response combined with FLC-MS Status. CR + FLC-MS negative, median OS, NR; CR + FLC-MS positive, 108 months; VGPR, FLC-MS negative, 78 months; VGPR + FLC-MS positive, 63 months.

Overall survival stratified by FLC-MS positivity or negativity: (A) OS from diagnosis based on FLC-MS status at 12-month landmark analysis; median OS, NR vs 63 months (P ≤ .001) in those with FLC-MS negative vs positive. (B) OS from diagnosis based on FLC-MS status at 12-month landmark analysis in patients who achieved a hematologic CR; median OS was NR vs 108 months (P = .009) in those with FLC-MS negative vs positive. (C) Six month analysis of OS from diagnosis by hematologic response combined with FLC-MS Status. CR – FLC MS negative, median OS NR, CR – FLC MS positive 80 months, VGPR – FLC MS negative 85 months, VGPR – FLC MS positive 60 months. (D) Twelve month analysis of OS from diagnosis by hematologic response combined with FLC-MS Status. CR + FLC-MS negative, median OS, NR; CR + FLC-MS positive, 108 months; VGPR, FLC-MS negative, 78 months; VGPR + FLC-MS positive, 63 months.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal